Rybelsus, the first and only ORAL GLP-1 agonisant, has been recognized again

Novo Nordisk's type 2diabetesdrug, the oral GLP-1 agonisant Rybelsus, has been approved for sale in JapanJapan's Ministry of Health, Labour (MHLW) approval was approved by the FDA in October last yearand in February by the European UnionRybelsus is by far the first and only oral drug for GLP-1 agonistsapproval is based on data from the PIONEER clinical trial, which was conducted among 9,500 subjects, including 1,300 Japanese patientsIn the study, Rybelsus, which controlled blood sugar once a day, was equivalent to Trulicity once a week, while the daily dose of 14 mg was better than Trulicity and Victoza, which were injected once a dayNew data from, reported at the American Diabetes Association meeting earlier this month, show that Rybelsus is better at reducinglow blood sugarand weight in people with type 2 diabetes, ahead of Merck's oral DPP-4 inhibitor Januvia, Bollinger Ingehan and Lilly's SGLT2 drosiance and VictozaIn a recent report, Johan Unnerus, an analyst at Pareto Securities, predicted that Rybelsus would generate more than $5 billion in revenue by 2026